Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06434350 · ClinicalTrials.gov registry record · Phase 1
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
A Phase 1 study of Advanced Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06434350: Recruiting Phase 1 study of Advanced Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06434350 is a Phase 1 study of Advanced Bladder Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06434350, a Phase 1 study of Advanced Bladder Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.0
Conditions Studied
Interventions
- DRUG Enfortumab Vedotin
- RADIATION Radiation Therapy
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-09-24 |
| Phase | Phase 1 |
What NCT06434350 shows while recruiting
NCT06434350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Advanced Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enfortumab Vedotin is the first listed.
NCT06434350 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06434350 about?
NCT06434350 is a clinical study titled "Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)". To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
What is the current status of trial NCT06434350?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-10-10. Estimated completion is 2027-09-24.
What conditions does trial NCT06434350 study?
This clinical trial studies the following conditions: Advanced Bladder Cancer.
What interventions are being tested in trial NCT06434350?
The interventions under investigation include: Enfortumab Vedotin (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06434350?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06434350 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06434350's enrollment target sits among peer trials
41 1126th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI